Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Eur J Clin Microbiol Infect Dis ; 36(7): 1261-1268, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28181033

ABSTRACT

Although extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae have become a worldwide public health concern, little is known regarding the clinical course of colonized or infected individuals. Our objective was to characterize the determinants of fatal outcomes related to ESBL-producing microorganisms at a large hospital in Paris, France. In 2012-2013, all consecutive patients with clinical samples testing positive for ESBL-producing Enterobacteriaceae at Saint-Antoine Hospital were identified. Patient clinical data were obtained at hospital entry, while information on intensive care unit (ICU) admissions and death were prospectively collected. Risk-factors for fatal 1-year outcomes were assessed using logistic regression. In total, 643/4684 (13%) ESBL-positive samples were observed, corresponding to 516 episodes (n = 206, 40% treated) among 330 patients. Most episodes were nosocomial-related (n = 347/516, 67%) involving Escherichia coli (n = 232/516, 45%) or Klebsiella pneumoniae (n = 164/516, 32%). Empirical antibiotic therapy was adequate in 89/206 (43%) infections, while the median length of hospital stay was 30 days [interquartile range (IQR) = 11-55] and 39/201 (19%) were admitted to the ICU. Overall, 104/241 patients (43%) with available data died within 1 year. In the multivariable analysis, 1-year death was associated with age >80 years (p = 0.01), concomitant comorbidity (p = 0.001), nosocomial-acquired infection (p = 0.002), and being infected rather than colonized (p < 0.001). In this series of patients with identified samples of ESBL-producing Enterobacteriaceae, hospital burden was large and 1-year mortality rates high. Understanding which patients in this setting would benefit from broad-spectrum empirical antibiotic therapy should be further examined.


Subject(s)
Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Age Factors , Aged , Aged, 80 and over , Female , Hospitals , Humans , Male , Middle Aged , Paris/epidemiology , Prospective Studies , Risk Factors , Survival Analysis , Treatment Outcome
3.
Intensive care med ; 41(7)July 2015.
Article in English | BIGG - GRADE guidelines | ID: biblio-965111

ABSTRACT

Emerging resistance to antibiotics shows no signs of decline. At the same time, few new antibacterials are being discovered. There is a worldwide recognition regarding the danger of this situation. The urgency of the situation and the conviction that practices should change led the Société de Réanimation de Langue Française (SRLF) and the Société Française d'Anesthésie et de Réanimation (SFAR) to set up a panel of experts from various disciplines. These experts met for the first time at the end of 2012 and have since met regularly to issue the following 67 recommendations, according to the rigorous GRADE methodology. Five fields were explored: i) the link between the resistance of bacteria and the use of antibiotics in intensive care; ii) which microbiological data and how to use them to reduce antibiotic consumption; iii) how should antibiotic therapy be chosen to limit consumption of antibiotics; iv) how can antibiotic administration be optimized; v) review and duration of antibiotic treatments. In each institution, the appropriation of these recommendations should arouse multidisciplinary discussions resulting in better knowledge of local epidemiology, rate of antibiotic use, and finally protocols for improving the stewardship of antibiotics. These efforts should contribute to limit the emergence of resistant bacteria.(AU)


Subject(s)
Humans , Bacterial Infections/drug therapy , Intensive Care Units, Pediatric , Drug Monitoring , Unnecessary Procedures , Drug Resistance, Bacterial , Anti-Infective Agents/therapeutic use
4.
J Microbiol Methods ; 110: 85-91, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25623509

ABSTRACT

The dissemination of antimicrobial resistance genes in Enterobacteriaceae has been largely attributed to plasmids, circular DNA molecules capable of autonomous replication. Whereas high-copy-number plasmids primarily rely on passive diffusion for plasmid maintenance, low-copy-number plasmids utilize so-called partition (par) systems. Plasmid partition relies on three structures, i.e. a centromere like DNA site, a centromere-binding protein and an ATPase or a GTPase motor protein for plasmid positioning. Identification and classification of plasmids is essential for tracing plasmids conferring drug resistance. PCR-based replicon typing is currently the standard method for plasmid identification but there are new classification schemes, especially the relaxase gene typing (PRaseT). Here we developed a multiplex PCR set targeting par loci found on the plasmids most frequently encountered in Enterobacteriaceae. This method, called "plasmid partition gene typing" (PAR-T), was validated with 136 transconjugants or transformants harboring various replicon types. The method was tested with 30 multidrug-resistant clinical isolates including Escherichia coli, Klebsiella pneumoniae and Salmonella enterica subsp. enterica carrying 1-4 replicons; all replicons were tested in parallel with PRaseT for comparison. Six multiplex PCRs and one simplex PCR including 18 pairs of primers recognized plasmids of groups IncA/C, FIA, FIB, FIC, FIIk, FII, HI1, HI2, I1, L/M, N, X. Our set of multiplex PCRs showed high specificity for the classification of resistance plasmids except for IncX replicons.


Subject(s)
Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli/genetics , Klebsiella pneumoniae/genetics , Plasmids/classification , Polymerase Chain Reaction , Salmonella enterica/genetics , Centromere/genetics , Computer Simulation , DNA/genetics , DNA Primers , Microbial Sensitivity Tests , Phylogeny , Plasmids/genetics , Replicon
6.
Euro Surveill ; 15(46)2010 Nov 18.
Article in English | MEDLINE | ID: mdl-21144428

ABSTRACT

We report the successful control of an outbreak caused by imipenem-resistant VIM-1-producing Klebsiella pneumoniae (IR-Kp) in France. This outbreak occurred in a care centre for abdominal surgery that includes a 15-bed liver intensive care unit and performs more than 130 liver transplantations per year. The index case was a patient with acute liver failure transferred from a hospital in Greece for urgent liver transplantation who was carrying IR-Kp at admission as revealed by routine culture of a rectal swab. Infection control measures were undertaken and included contact isolation and promotion of hand hygiene with alcohol-based hand rub solution. Nevertheless, secondary IR-Kp cases were identified during the six following months from 3 December 2003 to 2 June 2004. From 2 June to 21 October, extended infection control measures were set up, such as cohorting IR-Kp carriers, contact patients and new patients in distinct sections with dedicated staff, limiting ward admission, and strict control of patient transfer. They led to a rapid control of the outbreak. The global attack rate of the IR-Kp outbreak was 2.5%, 13% in liver transplant patients and 0.4% in the other patients in the care centre (p<0.005). Systematic screening for IR-Kp of all patients admitted to the care centre is still maintained to date and no secondary IR-Kp case has been detected since 2 June 2004.


Subject(s)
Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Infection Control/methods , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/isolation & purification , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Cross Infection/epidemiology , Cross Infection/microbiology , Drug Resistance, Bacterial , Female , France/epidemiology , Hospital Bed Capacity, 500 and over , Humans , Imipenem/pharmacology , Imipenem/therapeutic use , Intensive Care Units , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella Infections/prevention & control , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/enzymology , Liver Transplantation , Male , Microbial Sensitivity Tests , beta-Lactamases/metabolism
8.
Antimicrob Agents Chemother ; 53(9): 4002-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19596889

ABSTRACT

Analysis of 15 European clinical Enterobacteriaceae isolates showed that differences in the genetic context of blaCMY-2-like genes reflected the replicon type, usually IncA/C or IncI1. These blaCMY-2 loci may originate from the same ISEcp1-mediated mobilization from the Citrobacter freundii chromosome as structures described in earlier studies.


Subject(s)
Enterobacteriaceae/genetics , Plasmids/genetics , beta-Lactamases/genetics , Molecular Sequence Data , Polymerase Chain Reaction
9.
Antimicrob Agents Chemother ; 50(12): 4177-81, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16982793

ABSTRACT

We studied the genetic organization of bla(ACC-1) in 14 isolates of Enterobacteriaceae from France, Tunisia, and Germany. In a common ancestor, ISEcp1 was likely involved in the mobilization of this gene from the Hafnia alvei chromosome to a plasmid. Other genetic events involving insertion sequences (particularly IS26), transposons (particularly Tn1696), or sulI-type integrons have occurred, leading to complex genetic environments.


Subject(s)
Cross Infection/microbiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/enzymology , Genes, Bacterial , beta-Lactamases/genetics , Base Sequence , Chromosomes, Bacterial/genetics , DNA Transposable Elements/genetics , Enterobacteriaceae/isolation & purification , Hafnia alvei/genetics , Humans , Integrons/genetics , Molecular Sequence Data , Open Reading Frames , Plasmids/genetics
10.
Infect Control Hosp Epidemiol ; 22(1): 35-40, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11198020

ABSTRACT

OBJECTIVE: To describe an outbreak of imipenem-resistant Acinetobacter baumannii (IR-Ab) and the measures for its control, and to investigate risk factors for IR-Ab acquisition. DESIGN: An observational and a case-control study. SETTING: A surgical intensive care unit (ICU) in a university tertiary care hospital. METHODS: After admission to the ICU of an IR-Ab-positive patient, patients were prospectively screened for IR-Ab carriage upon admission and then once a week. Environmental cleaning and barrier safety measures were used for IR-Ab carriers. A case-control study was performed to identify factors associated with IR-Ab acquisition. Cases were patients who acquired IR-Ab. Controls were patients who were hospitalized in the ICU at the same time as cases and were exposed to IR-Ab for a similar duration as cases. The following variables were investigated as potential risk factors: baseline characteristics, scores for severity of illness and therapeutic intervention, presence and duration of invasive procedures, and antimicrobial administration. RESULTS: Beginning in May 1996, the outbreak involved 17 patients over 9 months, of whom 12 acquired IR-Ab (cases), 4 had IR-Ab isolates on admission to the ICU, and 1 could not be classified. Genotypic analysis identified two different IR-Ab isolates, responsible for three clusters. Ten of the 12 nosocomial cases developed infection. Control measures included reinforcement of barrier safety measures, limitation of the number of admissions, and thorough environmental cleaning. No new case was identified after January 1997. Eleven of the 12 cases could be compared to 19 controls. After adjustment for severity of illness, a high individual therapeutic intervention score appeared to be a risk factor for IR-Ab acquisition. CONCLUSION: The outbreak ended after strict application of control measures. Our results suggest that high work load contributes to IR-Ab acquisition.


Subject(s)
Acinetobacter Infections/epidemiology , Acinetobacter/drug effects , Anti-Bacterial Agents/pharmacology , Cross Infection , Imipenem/pharmacology , Acinetobacter/pathogenicity , Acinetobacter Infections/drug therapy , Adult , Aged , Case-Control Studies , Disease Outbreaks , Drug Resistance, Microbial , Female , Humans , Intensive Care Units , Male , Middle Aged , Risk Factors
11.
Crit Care Med ; 28(4): 962-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10809267

ABSTRACT

OBJECTIVE: To compare direct examination of bronchial aspirate and plugged telescopic catheter specimens (PTC) with infected cell counts in bronchoalveolar lavage (BAL) specimens for the diagnosis of nosocomial pneumonia. DESIGN: Prospective study of critically ill patients. SETTING: Intensive care unit in a university hospital. PATIENTS: A total of 64 patients hospitalized for >48 hrs with suspected nosocomial pneumonia. INTERVENTIONS: Fiberoptic bronchoscopy with bronchial aspirate and quantitative protected specimen brush, PTC, and BAL cultures. PTC and bronchial aspirate specimens were Gram-stained. BAL specimens for infected cell counts were examined as described previously in the literature. MEASUREMENTS AND MAIN RESULTS: Nosocomial pneumonia was diagnosed by the medical staff based on all available clinical, radiologic, laboratory test, and microbiological data and on the course before and after appropriate therapy. A total of 71% of patients were ventilated, and 70.1% were receiving antibiotics. Nosocomial pneumonia was diagnosed in 54% of the cases. On direct examination, sensitivity (Se) and specificity (Sp) of bronchial aspirate specimens were Se, 82% and Sp, 60%; of BAL with 5% infected cells, Se, 56% and Sp, 100%; of BAL with 3% infected cells, Se, 74% and Sp, 96%; of PTC specimens, Se, 65% and Sp, 76%; and of PTC specimens plus BAL with 3% infected cells, Se, 83% and Sp, 78%. BAL with 3% infected cells was significantly better for predicting nosocomial pneumonia than direct examination of bronchial aspirate or PTC specimens (p = .0012). When the BAL showed 3% infected cells, neither direct examination of bronchial aspirate nor direct examination of PTC specimens was useful (p = .24 and p = .38, respectively). Combined use of direct examination of PTC specimens plus BAL with 3% infected cells markedly improved sensitivity. The total cost of each procedure was taken into account for the final evaluation. CONCLUSIONS: Our data suggest that BAL with 3% infected cells is currently the only test whose predictive value for nosocomial pneumonia is sufficiently high to be of use for guiding the initial choice of antimicrobial class while waiting for quantitative culture results.


Subject(s)
Bronchoscopy/methods , Cross Infection/diagnosis , Pneumonia, Bacterial/diagnosis , Adult , Aged , Bronchoalveolar Lavage/economics , Bronchoalveolar Lavage/methods , Bronchoalveolar Lavage/statistics & numerical data , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/microbiology , Bronchoscopy/economics , Bronchoscopy/statistics & numerical data , Costs and Cost Analysis , Cross Infection/economics , Female , Humans , Male , Middle Aged , Pneumonia, Bacterial/economics , Prognosis , Prospective Studies , Sensitivity and Specificity
12.
Pathol Biol (Paris) ; 48(8): 733-44, 2000 Oct.
Article in French | MEDLINE | ID: mdl-11244602

ABSTRACT

Diarrhea that occurs in hospitalized patients is frequent and may be due to infectious or noninfectious causes. In adults with nosocomial diarrhea, the most commonly detected agent is Clostridium difficile; in children, rotaviruses are predominant. Various studies have shown that bacterial enteric pathogens (e.g. Salmonella spp., Shigella spp., Campylobacter spp...) or parasites are common causes of community-acquired diarrhea but rarely cause nosocomial enteritis. Stool cultures for these pathogens and ova and parasite examination should not be performed in patients hospitalized for more than three days unless there are plausible clinical or epidemiological reasons to do so. In contrast, C. difficile toxins assay (and rotavirus screening in children) should be primarily requested. The detection of C. difficile toxin B by stool cytotoxicity assay remains the 'gold standard'. Identification of toxin A (or A + B) can also be performed by immuno-enzymatic (ELISA) tests: results may be obtained in three hours. Electronic microscopy is the standard method for rotavirus diagnosis but tests using latex agglutination or immuno-enzymatic assay are now available. Various typing methods have been developed and may be routinely used in epidemiological investigations.


Subject(s)
Cross Infection/diagnosis , Cross Infection/microbiology , Diarrhea/microbiology , Laboratories , Adult , Child , Clostridioides difficile/isolation & purification , Clostridium Infections/diagnosis , Diarrhea/epidemiology , Feces/microbiology , Hospitals , Humans , Rotavirus/isolation & purification , Rotavirus Infections/diagnosis
13.
Clin Infect Dis ; 29(6): 1411-8, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10585788

ABSTRACT

Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLPE) were isolated from clinical specimens from 130 to 140 patients/year in 1989-1991 in our hospital. In February 1992, a control program was initiated: screening tests in 3 intensive care units (ICUs) and contact-isolation precautions in all units. The septic surgical unit served as an isolation ward for surgical patients from whom ESBLPE was isolated. In 1992, the incidence of ESBLPE acquisition failed to decrease, and most acquisitions occurred in 3 ICUs. Critical evaluation of implementation of isolation procedures in these ICUs prompted corrective measures for barrier precautions. The incidence of acquired cases subsequently decreased, and a second evaluation determined that these measures had been correctly applied. The incidence of acquired cases in the septic surgical unit was lower than those in the other units. Decreases were also found in the incidence of acquisition of other hand-transmitted multidrug-resistant organisms. Barrier precautions, screening tests for ICU patients, and grouping of cohorts after ICU discharge are effective in controlling the spread of multidrug-resistant microorganisms by cross-contamination. The outbreak was effectively controlled without restricting antimicrobial use.


Subject(s)
Cross Infection/prevention & control , Enterobacteriaceae Infections/prevention & control , Enterobacteriaceae/isolation & purification , Hospitals, University/statistics & numerical data , beta-Lactamases/biosynthesis , Anti-Bacterial Agents/therapeutic use , Cephalosporins/therapeutic use , Cross Infection/epidemiology , Cross Infection/microbiology , Disease Outbreaks , Drug Resistance, Microbial , Drug Resistance, Multiple , Enterobacteriaceae/drug effects , Enterobacteriaceae/enzymology , Enterobacteriaceae Infections/epidemiology , Humans , Imipenem/therapeutic use , Infection Control , Intensive Care Units/statistics & numerical data , Paris/epidemiology
14.
Clin Infect Dis ; 29(5): 1231-8, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10524968

ABSTRACT

In the surgical intensive care unit of a university hospital, we investigated the frequency of and the risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) during postoperative intra-abdominal infection (pIAI). We conducted a prospective MRSA nasal screening and case evaluation for 17 months among 73 consecutive patients with having pIAI. MRSA pIAI was diagnosed when MRSA was obtained from culture of intraperitoneal fluids. The identity of nasal and peritoneal MRSA strains was assessed by genomic analysis. Twelve patients had MRSA pIAI, representing 21% of all MRSA infections acquired by the 73 patients. An organ system failure score of >/=1 and MRSA nasal carriage prior to pIAI were the independent risk factors for acquisition of MRSA pIAI. Patients with MRSA pIAI had a longer intensive care unit stay and more reoperations than did those free of MRSA pIAI. We conclude that MRSA may be a causative pathogen in pIAI and may be related to nasal colonization.


Subject(s)
Ascitic Fluid/microbiology , Methicillin Resistance , Nasal Mucosa/microbiology , Postoperative Complications/etiology , Staphylococcal Infections/etiology , Staphylococcus aureus/drug effects , Adult , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Risk Factors , Staphylococcus aureus/isolation & purification
15.
Antimicrob Agents Chemother ; 43(11): 2607-11, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10543736

ABSTRACT

Glycopeptides (vancomycin and teicoplanin) and metronidazole are the drugs of choice for the treatment of Clostridium difficile infections, but trends in susceptibility patterns have not been assessed in the past few years. The objective was to study the MICs of glycopeptides and metronidazole for unrelated C. difficile strains isolated in 1991 (n = 100) and in 1997 (n = 98) by the agar macrodilution, the E-test, and the disk diffusion methods. Strain susceptibilities to erythromycin, clindamycin, tetracycline, rifampin, and chloramphenicol were also determined by the ATB ANA gallery (bioMérieux, La Balme-les-Grottes, France). The MICs at which 50% of isolates are inhibited (MIC(50)s) and MIC(90)s of glycopeptides and metronidazole remained stable between 1991 and 1997. All the strains were inhibited by concentrations that did not exceed 2 microgram/ml for vancomycin and 1 microg/ml for teicoplanin. Comparison of MICs determined by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards and the E test showed correlations (+/-2 dilutions) of 86. 6, 95.9, and 99% for metronidazole, vancomycin, and teicoplanin, respectively. The E test always underestimated the MICs. Strains with decreased susceptibility to metronidazole (MICs, >/=8 microgram/ml) were isolated from six patients (n = 4 in 1991 and n = 2 in 1997). These strains were also detected by the disk diffusion method (zone inhibition diameter, /=1 microgram/ml), clindamycin (MICs, >/=2 microgram/ml), tetracycline (MICs, >/=8 microgram/ml), rifampin (MICs, >/=4 microgram/ml), and chloramphenicol (MICs, >/=16 microgram/ml) was observed in 64.2, 80.3, 23.7, 22.7, and 14.6% of strains, respectively. Strains isolated in 1997 were more susceptible than those isolated in 1991, and this trend was correlated to a major change in serogroup distribution. Periodic studies are needed in order to detect changes in serogroups and the emergence of strains with decreased susceptibility to therapeutic drugs.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clostridioides difficile/drug effects , Glycopeptides , Metronidazole/pharmacology , Adult , Bacterial Toxins/metabolism , Clostridioides difficile/metabolism , Culture Media , Diffusion , Drug Resistance, Microbial , Enterocolitis, Pseudomembranous/drug therapy , Enterocolitis, Pseudomembranous/microbiology , France , Humans , Microbial Sensitivity Tests , Serotyping
16.
J Antimicrob Chemother ; 43 Suppl C: 67-70, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10404341

ABSTRACT

The aim of this study was to assess the serum bactericidal activity (SBA) of levofloxacin compared with that of ofloxacin against methicillin-resistant Staphylococcus aureus (MRSA) isolates. Serum from 10 healthy volunteers (seven females, three males) was collected after a single oral dose of either levofloxacin (500 mg) or ofloxacin (400 mg). Subjects were allocated randomly to treatment after at least a 1 week interval between antibiotic regimens. Three well-defined MRSA strains were tested, each susceptible to levofloxacin and ofloxacin, with different levels of resistance to methicillin (HBD 456, HBD 3 and HBD 2; class 1, 2 and 3 Tomasz heterogeneous resistance, respectively) together with a methicillin-susceptible (MSSA) reference strain (S. aureus ATCC 25,923). SBA was tested in vitro by a microtitration method 15 min before dosing and at 1, 4, 8 and 12 h after drug absorption. Levofloxacin was significantly more bactericidal than ofloxacin against all strains of S. aureus tested (SBA > or = 1:2). An SBA was recorded for only a short period with ofloxacin, and thereafter only bacteriostatic activity remained. This study, therefore, confirms the superior activity of levofloxacin over that of ofloxacin against MSSA and MRSA.


Subject(s)
Anti-Infective Agents/pharmacology , Levofloxacin , Ofloxacin/pharmacology , Staphylococcus aureus/drug effects , Humans , Methicillin Resistance , Microbial Sensitivity Tests , Serum Bactericidal Test , Staphylococcus aureus/isolation & purification
17.
Clin Infect Dis ; 27(4): 834-44, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9798042

ABSTRACT

The epidemiology of extended-spectrum beta-lactamase (ESBL)-producing strains of Klebsiella pneumoniae was studied over a 16-month period in a medical intensive care unit (ICU). A control program involving enhanced isolation procedures, surveillance cultures at admission and then at 1-week intervals, and selective digestive decontamination (SDD) was instituted. Phenotypic and genotypic markers (plasmid content and DNA macrorestriction polymorphism determined by pulsed-field gel electrophoresis) were used to compare 138 strains of ESBL-producing K. pneumoniae. The incidence of colonization and/or infection with ESBL producers was 11.9%. ESBL-producing K. pneumoniae strains were isolated from 64 of 65 patients. Fifty-five cases were considered acquired in the ICU, while nine cases were imported. Forty-five infections occurred in 32 patients; 20 infections involved the urinary tract. SDD failed to reduce the incidence of acquisition of ESBL-producing K. pneumoniae. Combined use of markers was necessary to achieve accurate differentiation of strains. A single epidemic clone (SHV-4 beta-lactamase-producing K. pneumoniae) was the cause of 85% of the ICU-acquired cases. Sporadic occurrence of SHV-5, TEM-3, SHV-2, and SHV-3 producers accounted only for a few cases.


Subject(s)
Cross Infection/microbiology , Intensive Care Units , Klebsiella Infections/epidemiology , Klebsiella Infections/microbiology , Klebsiella pneumoniae , Cross Infection/epidemiology , DNA Fingerprinting , DNA, Bacterial/analysis , Drug Resistance, Microbial/genetics , Electrophoresis, Gel, Pulsed-Field , Genome, Bacterial , Genotype , Humans , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Paris/epidemiology , Phenotype , Plasmids/analysis , Polymerase Chain Reaction/methods , beta-Lactamases
18.
Presse Med ; 26(10): 485-92, 1997 Mar 29.
Article in French | MEDLINE | ID: mdl-9137377

ABSTRACT

UNLABELLED: BETA-LACTAMASE: The capacity to produce beta-lactamase, an enzyme which hydrolyses penicillin and cephalosporines, is the main source of bacterial resistance to beta-lactamines, thus the important contribution of beta-lactamase inhibitors (clavanulanic acid, sulbactam and tazobactam). MECHANISM OF ACTION: Beta-lactamase inhibitors inactivate these enzymes and, in association with beta-lactamines, offer wide spectrum bactericidal action (Gram negative bacilli, anaerobic germs, methicillin-sensitive staphylococci and streptococci) and can be used as first-line treatment in certain community-acquired and nosocomial infections. SIDE EFFECTS: Widespread use of these inhibitors selects intermediate or resistant strains. Toxicity is low. Undesirable effects (poor digestive tolerance for oral formulations) are dose-dependent. RIGOROUS PRESCRIPTION: Recent development of bacterial resistance emphasizes the importance of rational use of these associations and the need for a better definition of the optimal doses. Prescriptions must avoid underdosing and excessively long treatments. Treatment should be simplified if sensitivity to an antibiotic with a narrower spectrum is recognized.


Subject(s)
Enzyme Inhibitors/therapeutic use , beta-Lactamase Inhibitors , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Therapy, Combination/pharmacology , Drug Therapy, Combination/therapeutic use , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , beta-Lactams
20.
Clin Infect Dis ; 22(3): 430-6, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8852958

ABSTRACT

A prospective study was initiated in an intensive care unit (ICU) where extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLPE) were endemic. From July 1990 to July 1991, patients hospitalized for > or = 5 days were screened for ESBLPE acquisition by means of weekly rectal sampling and clinical cultures. Baseline characteristics and various ICU procedures in 62 cases of ESBLPE were compared with those for 205 patients without ESBLPE, with use of Cox's model. Risk for acquiring ESBLPE (Klebsiella pneumoniae in most cases) increased during the ICU stay, from 4.2% in the first week to 24% in the fourth week. Baseline characteristics were not different between the two groups. Urinary catheterization (P = .04) and arterial catheterization (P = .03) were independent risk factors for acquiring ESBLPE and probably reflected frequency of health care manipulations. The first site of ESBLPE acquisition was the digestive tract in 58 of the 62 patients; 28 infections developed in 22 patients, and these followed or occurred simultaneously with rectal colonization in 18 of those 22. DNA macrorestriction analysis suggested that the same strain was responsible for most cases. In conclusion, ESBLPE acquisition depends on length of stay in the ICU and the use of invasive procedures. Colonization is a prerequisite for infection.


Subject(s)
Disease Outbreaks , Drug Resistance, Multiple , Intensive Care Units , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/isolation & purification , beta-Lactam Resistance , Adult , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/epidemiology , Female , Humans , Klebsiella Infections/microbiology , Male , Prospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...